The primary clinical indication of carbetocin injection 100 mcg/ml is the prevention of uterine atony and subsequent reduction in the risk of postpartum hemorrhage following elective cesarean section.Cesarean section is a common obstetric intervention. According to the World Health Organization, its global incidence is approximately 15%, with substantial variation across countries and regions, reaching up to 52% in some nations. Due to uterine myometrial trauma during surgery, inhibitory effects of anesthetic agents on uterine contractility, and individual maternal differences, the incidence of uterine atony after cesarean section is significantly higher than that after vaginal delivery. Uterine atony is the leading cause of postpartum hemorrhage, which in severe cases can lead to maternal hemorrhagic shock, disseminated intravascular coagulation, and even death. Therefore, timely prevention of uterine atony in the postoperative period is critical.

Compared with conventional di-sipidin, the product demonstrates distinct advantages in preventing post‑cesarean uterine atony, particularly in duration of action, ease of administration, and stability of clinical effect, as detailed below:

First, it has a significantly longer duration of action and superior long‑acting properties. Conventional di-sipidin has a short half‑life of only 4–10 minutes, with limited sustained uterine contractile effect. It typically requires continuous intravenous infusion to maintain therapeutic effect for postpartum hemorrhage prophylaxis, which increases nursing workload and may cause excessive or insufficient uterine contractions due to inappropriate infusion rates.

As a long‑acting di-sipidin analog, carbetocin exhibits biphasic elimination after intravenous administration, with a median terminal elimination half‑life of up to 33 minutes; the half‑life is even longer after intramuscular injection, with some studies showing sustained efficacy for several hours.

Continuous intravenous infusion is unnecessary, providing stable and prolonged uterine contraction and avoiding the need for repeated dosing or continuous infusion required for conventional di-sipidin.

Second, it is convenient to administer and simplifies clinical procedures. For postpartum hemorrhage prophylaxis after cesarean section, conventional di-sipidin requires an immediate intravenous bolus followed by continuous infusion for 4–6 hours, with strict rate control and considerable consumption of nursing resources. By contrast, carbetocin injection 100 mcg/ml only requires slow intravenous injection after fetal delivery, before or after placental delivery, with no need for subsequent continuous infusion. The simple administration regimen significantly reduces nursing workload, especially in busy obstetric settings, and lowers risks associated with improper infusion practices.

In addition to prophylaxis of post‑cesarean uterine atony, the product may be used as an adjunctive agent in combination with other uterotonics (e.g., conventional oxytocin, ergometrine, prostaglandins) for the emergency treatment of refractory postpartum hemorrhage.Postpartum hemorrhage is the leading cause of maternal mortality worldwide, affecting over 14 million women annually and resulting in 70,000 maternal deaths. Uterine atonic hemorrhage accounts for 70%–80% of postpartum hemorrhage cases. This condition is life‑threatening and requires rapid combination therapy with multiple uterotonics to enhance uterine contraction, control bleeding, and save the mother's life.